http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM#Head
http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM#assertion
http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM#provenance
http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM#pubinfo
http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM#assertion
http://purl.obolibrary.org/obo/DOID_5844
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_5844
http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB01079
http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM#association
http://www.w3.org/2000/01/rdf-schema#label
"ZELNORM is contraindicated in patients with: A history of myocardial infarction (MI), stroke, transient ischemic attack (TIA), or angina [see Warnings and Precautions (5.1) A history of ischemic colitis or other forms of intestinal ischemia [see Warnings and Precautions (5.2) Severe renal impairment (eGFR< 15 mL/min/1.73 m 2 [see Use in Specific Populations (8.6) Moderate and severe hepatic impairment (Child-Pugh B or C) [see Use in Specific Populations (8.7) A history of bowel obstruction, symptomatic gallbladder disease, suspected sphincter of Oddi dysfunction, or abdominal adhesions [see Adverse Reactions (6.2) Hypersensitivity to tegaserod [see Adverse Reactions (6.2) ZELNORM is contraindicated in patients with: A history of myocardial infarction, stroke, transient ischemic attack, or angina. ( 4 5.1 A history of ischemic colitis or other forms of intestinal ischemia. ( 4 5.2 Severe renal impairment (eGFR< 15 mL/min/1.73 m 2 4 8.6 Moderate or severe hepatic impairment (Child-Pugh B or C). ( 4 8.7 A history of bowel obstruction, symptomatic gallbladder disease, suspected sphincter of Oddi dysfunction, or abdominal adhesions. ( 4 Hypersensitivity to tegaserod. ( 4"
http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM#association
https://w3id.org/biolink/vocab/relation
https://schema.org/MedicalContraindication
https://identifiers.org/drugbank:DB01079
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM#provenance
http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM#pubinfo
http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM#sig
http://purl.org/nanopub/x/hasSignature
HMpAN/ZLAiirJ0dlGD2UuaPZ7LKEBwrf2JA4ZsjRPcg2IJ0rov5ynpWH9odQraW2JKDIExFrpyJqG7XB53q9ysnb6ceOxqO1r1BhZH20ivER7b12CBzWRThwvtaYTJxibEkRo5mG6J7G2XX+oPaTclLx92lBGH8NkaFT7RTPUhI=
http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM
http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM
http://purl.org/dc/terms/created
2021-08-23T19:01:06.583+02:00
http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY